Acne vulgaris is a chronic inflammatory skin disease involving the pilosebaceous unit,
affecting approximately 95% of adolescents and young adults.
Follicular hyperkeratinization, increased sebum production, androgen hormones and
inflammation play a role in the pathogenesis of acne. Androgens (Testosterone, DHEA-S and
DHT) play a role in the development of acne, hypertrophy of the sebaceous glands and
increased sebum production. Androgen receptors are located in the basal layer of the
sebaceous glands keratinocytes and they are located in the outer sheath of the hair follicle.
These receptors are responsible for the proliferative action of keratinocytes.
The relationship between androgen hormones and acne in women and prepubertal children is well
known. Many studies have shown a strong association between acne and hyperandrogenism in
women.
Systemic isotretinoin therapy can be used in patients with severe acne vulgaris who do not
respond to topical and oral antibiotic treatments.
In recent studies, it has been shown that systemic isotretinoin used in acne treatment
changes many hormones such as GnRH, FSH, LH, Estrogen, Progesterone, Testosterone, TSH, T4
and Prolactin and causes side effects such as menstrual irregularity and hirsutism.
However, data on the effect of oral isotretinoin on adrenal and sex hormones are
contradictory.
In this study, it was aimed to evaluate the effect of oral isotretinoin on adrenal steroid
and sex hormone levels and to compare it with a healthy control.
Isotretinoin treatment is started in acne vulgaris patients at a dose of 0.5-0.8mg/kg/day.
The total cumulative dose is 120 mg/kg.
At baseline and at the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS,
Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH
Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol,
Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated with LCMS/MS technique.
In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG,
TSH, T4 hormone levels of the patients will be evaluated by ELISA method.
In the baseline 2nd, 3rd, 4th and 6th months of the treatment and 3 months after the
treatment, the patients' height, weight, body mass index measurements, VAS scoring of patient
treatment satisfaction, Global Acne Severity Score, Acne Quality of Life Score, and Modified
Ferriman Gallwey Score for hirsutism will be recorded.
The side effects of isotretinoin such as menstrual irregularity, increased hair growth, and
cheilitis, dryness of the oral mucosa, skin dryness, dermatitis seen in patients during
treatment will be recorded.
*Hormone tests were performed on 2th and 3rd days of menstruation